Document is current
Any future updates will be listed below
-
Authors
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02424305 at ClinicalTrials.govDocuments that mention this clinical trial
Pharmacokinetics and Safety of Ingenol Disoxate Gel Administered Under Maximum-Use Conditions to Patients With Actinic Keratosis
https://doi.org/10.1007/s40261-017-0608-y
-
Funding
Funding for this research was provided by:
LEO Pharma
- License Information
-
More Information
Article History
First Online: 4 December 2017
Compliance with Ethical Standards
: The clinical trial protocol and any relevant amendments to the clinical trial protocol were approved by/received favorable opinion from the relevant Institutional Review Boards prior to the enrolment of patients. This clinical trial was conducted in accordance with the revision, current at the start of the trial, of the World Medical Association’s Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects.
: Edward Lain has received consulting fees or honorarium from LEO Pharma and Gage Pharmaceuticals. Torsten Skov and Anders Hall are employees of LEO Pharma A/S.
: All patients received written and verbal information regarding the clinical trial. The patient’s signed and dated informed consent to participate in the clinical trial was obtained prior to any trial-related activities being carried out in accordance with the International Conference on Harmonization.
: This study was funded by LEO Pharma.
: LEO Pharma was involved in the design and conduct of the trial; collection, management, analysis, and interpretation of data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.
